Our Future Health has welcomed the first new members to its Board of Trustees.
Role of the Board of Trustees
Our Future Health is governed by a Board of Trustees, which is responsible for the policies, activities and assets of Our Future Health and provides strategic leadership. Trustees serve on the Board in a voluntary capacity and do not receive remuneration.
New members of the Board of Trustees
By expanding our Board of Trustees, we’re bringing in additional skills, new ideas and diverse, independent perspectives to support the scale-up of our programme and to guide us through the years ahead. As part of the Board, our new Trustees will guide and shape the next phase of our programme and provide strategic leadership to Our Future Health. The new Trustees are:
Peter is a Trustee of Cancer Research UK and Chair of Cancer Research Technology Ltd, the commercialisation arm of Cancer Research UK. He is also Chair of Immatics N.V., a biopharmaceutical company developing new cancer immunotherapy treatments. He has been a Director of a number of public and private healthcare and life science companies, and was Chief Executive Officer of Cambridge Antibody Technology plc prior to its acquisition by AstraZeneca in July 2006.
Adrian currently serves as a non-executive Director at Unilever, J Sainsbury and Oxford Nanopore Technologies and is an external member of Oxford University Press. Previously, he spent 18 years in Chief Financial Officer roles at three FTSE 100 companies, Reckitt Benckiser, Smith & Nephew and Invensys. Prior to this, he spent 18 years at GSK working in finance and operations roles, including five years on the Research and Development leadership team of GlaxoWellcome/GSK. He was also previously a non-executive Director at RELX, Indivior, Bioventus, Affymetrix, Maxygen, Gray Cancer Research, Watford and Mount Vernon NHS Trust. He has an MA in Law and Economics from Cambridge University.
Kemal has 30 years of experience in global pharmaceutical research and development. He has been responsible for bringing many innovative medicines through Research and Development to successful commercialisation. From 2014 to 2019 he served as a member of the Board of Management of Bayer AG, responsible for innovation across the Bayer group. Prior to this he was Head of Global Development and Chief Medical Officer at Bayer Healthcare for ten years. He began his career in the pharmaceutical industry at Bristol-Myers Squibb, with responsibilities in medical affairs and clinical development. He is a non-executive Director at Syncona and was formerly a non-executive Director at Acceleron Pharma. Kemal qualified in medicine at Imperial College School of Medicine, London. He is a member of the Royal College of Physicians.
Richard is a Fellow of the Institute of Chartered Accountants and was a Partner in PricewaterhouseCoopers LLP (PwC) from 1992 until 2018, where he was lead Partner on a diverse range of FTSE 100 and Fortune 500 clients. He also held a number of senior management roles in PwC including Vice Chairman, Global Assurance from 2013 to 2018. He is on the Board and Chair of the Audit Committee of Northumbrian Water Limited and Co-Chair of the Value Reporting Foundation.
Welcoming the new Trustees, Professor Sir John Bell, Chair of Our Future Health, said:
Andrew Roddam, Chief Executive of Our Future Health, added:
Our Board of Trustees and Executive Team are supported by a range of advisory boards that provide expert guidance on important aspects of our programme, including ethics, science, diversity and technology. More details about these groups and our wider governance structure can be read here.